Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions
CachexiaNon-Small-Cell Lung CancerPancreatic CancerColorectal Cancer
Interventions
DRUG

PF-06946860

subcutaneous injection

Trial Locations (10)

20817

American Oncology Partners of Maryland, PA, Bethesda

20874

American Oncology Partners of Maryland, PA, Germantown

27710

Duke Cancer Center, Durham

32308

Tallahassee Memorial Healthcare Cancer Center, Tallahassee

46804

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

80033

Lutheran Medical Center, Wheat Ridge

81501

SCL Health Cancer Centers of Colorado - St. Mary's Hospital and Regional Medical Center, Grand Junction

90211

Beverly Hills Cancer Center, Beverly Hills

98108

VA Puget Sound Health Care System, Seattle

04074

New England Cancer Specialists, Scarborough

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04299048 - Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia. | Biotech Hunter | Biotech Hunter